Home Novartis announces FDA approval of Entresto to reduce risk of...
 

Keywords :   


Novartis announces FDA approval of Entresto to reduce risk of...

2015-07-09 05:43:33| Biotech - Topix.net

Novartis announced today that the US Food and Drug Administration has approved Entresto tablets, previously known as LCZ696, to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction . It is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other angiotensin receptor blocker .

Tags: of risk reduce approval

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.06VW to invest up to $5bn in Tesla rival Rivian
26.06Strategic use of soybean meal to maximize hog carcass weight during summer
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06Aer Lingus pilots begin industrial action over pay dispute
25.06Water requirements in the summer
25.06New model Is transforming the study of liver abscesses in cattle
25.06Royal Mail buyer to make offer for all staff shares
More »